Randomized Trialhigh evidence
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
Lancet (London, England)·July 13, 2024·PMID 38772405
Why it mattersIt provides the longest-term evidence that early intensive glycemic control yields near-lifelong cardiovascular and mortality benefits, reinforcing the importance of early intervention in type 2 diabetes.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled